Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/49674| Title: | Pharmacogenetic testing to identify presence of the HLA-B*57:01 biomarker for abacavir treatment |
| Authors: | Camilleri, Leanne Wirth, Francesca Azzopardi, Lilian M. |
| Keywords: | HLA-B Antigens Antiretroviral agents Pharmacogenetics -- Testing Personalized medicine |
| Issue Date: | 2019-09 |
| Publisher: | University of Malta. Department of Pharmacy |
| Citation: | Camilleri, L., Wirth, F., & Azzopardi, L. M. (2019, September). Pharmacogenetic testing to identify presence of the HLA-B*57:01 biomarker for abacavir treatment. Poster session presented at the FIP World Congress of Pharmacy and Pharmaceutical Sciences, Abu Dhabi, United Arab Emirates. |
| Abstract: | A poster presentation regarding pharmacogenetic testing to identify presence of the HLA-B*57:01 biomarker for abacavir treatment. Introduction: Testing for the HLA-B*57:01 biomarker is clinically significant to predict the risk of potentially life-threatening hypersensitivity reactions in patients to be treated with the antiretroviral drug abacavir. Screening for HLA-B*57:01 is required prior to initiating abacavir therapy and alternative therapy should be prescribed in patients who test positive for the biomarker. Aim: To review and compare genotyping methods for the identification of the HLA-B*57: pharmacogenetic biomarker in relation to abacavir treatment. |
| URI: | https://www.um.edu.mt/library/oar/handle/123456789/49674 |
| Appears in Collections: | Scholarly Works - FacM&SPha |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Pharmacogenetic_testing_to_identify_presence_of_the_HLA_B_57_01_biomarker_for_abacavir_treatment_2019.pdf | 665.95 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.